fMRI in Rodents – from Bold Activity Readouts to Large Scale Networks Interactions
Event details
| Date | 30.01.2017 |
| Hour | 12:15 |
| Speaker | Prof. Markus Rudin, Institute for Biomedical Engineering, ETHZ, Zurich (CH) |
| Location | |
| Category | Conferences - Seminars |
DISTINGUISHED LECTURE IN BIOLOGICAL ENGINEERING
(sandwiches served)
Abstract:
Functional magnetic resonance imaging (fMRI) in rodents is attractive in many regards. Mechanistic information on the link of the hemodynamic response to the underlying neural activity can be obtained by combining fMRI with established invasive readouts of neuronal function. Use of genetically engineered mouse lines allows assessing the impact of specific molecular entities involved in signal processing. The relatively simple (cortical) morphology enables detailed analyses of the functional topology and its rearrangements following CNS injury and full three-dimensional brain coverage the identification of large scale networks involved in a specific task, during pharmacological activation or at rest.
Challenges in rodent fMRI are linked to the small dimensions and corresponding high demands on spatial resolution, to the animal physiology, which should be stable enough to allow for detection of percent changes in signal intensity, and to the potential interference by anesthesia. Technical solutions are available and rodent (mouse) fMRI is becoming a commodity.
Different aspects of rodent fMRI will be addressed: 1) Mechanistic information on the neurovascular coupling obtained by combined fMRI with complementary activity readouts, 2) structural and functional connectivity in mouse brain, 3) dynamic aspects of functional connectivity, 4) investigation neurotransmitter networks using optogenetic approaches, and 5) analysis of the impact of pathological conditions such as cerebral amyloidosis mimicking aspects of Alzheimer’s disease, chronic psychosocial stress (CPS), and early life stress on brain functional networks.
Bio:
Markus Rudin is full professor for Molecular Imaging and Functional Pharmacology at the Institute for Biomedical Engineering (D-ITET) since June 2006. Since March 2005 he is also full professor for Molecular Imaging and Functional Pharmacology at the University of Zürich both at the Institute for Biomedical Engineering and the Institute for Pharmacology and Toxicology.
Markus Rudin (born 1953, from Lauwil BL) received his diploma in chemistry at the ETHZ in 1976 and his PhD at the Laboratory for Physical Chemistry in 1981 in the field of electron spin resonance / electron-nuclear double resonance, followed by a post-doctorate in the same area. In 1983 he moved to biomedical imaging, joining Sandoz AG to build up a biomedical imaging group initially focused on magnetic resonance imaging. He received his basic training in imaging at the Biocenter of the University of Basel. Within Sandoz AG, later Novartis Pharma AG, he became head of the Biophysics Group, head of the In-vivo Models Unit and finally head of the Analytical and Imaging Science Unit within Discovery Technologies at the Novartis Institutes for Biomedical Research. In this function he was also deputy head of Discovery Technologies until 2005. In 1997 he became Privat Dozent for Biophysics at the University of Basel. Since March 2005, he is member of the Research Council of the Swiss National Science Foundation.
Markus Rudin is heading a research group at the animal imaging center of UZH and ETH located at ETH Hönggerberg focusing on MRI and optical imaging methods (fluorescence tomography). His research focus is the development of non-invasive imaging techniques for studying structure, physiology, and metabolism of tissue as well as cellular and molecular events in the intact organism, in particular assays for monitoring signal transduction pathways. Biomedical applications are in neuroscience and metabolic diseases.
(sandwiches served)
Abstract:
Functional magnetic resonance imaging (fMRI) in rodents is attractive in many regards. Mechanistic information on the link of the hemodynamic response to the underlying neural activity can be obtained by combining fMRI with established invasive readouts of neuronal function. Use of genetically engineered mouse lines allows assessing the impact of specific molecular entities involved in signal processing. The relatively simple (cortical) morphology enables detailed analyses of the functional topology and its rearrangements following CNS injury and full three-dimensional brain coverage the identification of large scale networks involved in a specific task, during pharmacological activation or at rest.
Challenges in rodent fMRI are linked to the small dimensions and corresponding high demands on spatial resolution, to the animal physiology, which should be stable enough to allow for detection of percent changes in signal intensity, and to the potential interference by anesthesia. Technical solutions are available and rodent (mouse) fMRI is becoming a commodity.
Different aspects of rodent fMRI will be addressed: 1) Mechanistic information on the neurovascular coupling obtained by combined fMRI with complementary activity readouts, 2) structural and functional connectivity in mouse brain, 3) dynamic aspects of functional connectivity, 4) investigation neurotransmitter networks using optogenetic approaches, and 5) analysis of the impact of pathological conditions such as cerebral amyloidosis mimicking aspects of Alzheimer’s disease, chronic psychosocial stress (CPS), and early life stress on brain functional networks.
Bio:
Markus Rudin is full professor for Molecular Imaging and Functional Pharmacology at the Institute for Biomedical Engineering (D-ITET) since June 2006. Since March 2005 he is also full professor for Molecular Imaging and Functional Pharmacology at the University of Zürich both at the Institute for Biomedical Engineering and the Institute for Pharmacology and Toxicology.
Markus Rudin (born 1953, from Lauwil BL) received his diploma in chemistry at the ETHZ in 1976 and his PhD at the Laboratory for Physical Chemistry in 1981 in the field of electron spin resonance / electron-nuclear double resonance, followed by a post-doctorate in the same area. In 1983 he moved to biomedical imaging, joining Sandoz AG to build up a biomedical imaging group initially focused on magnetic resonance imaging. He received his basic training in imaging at the Biocenter of the University of Basel. Within Sandoz AG, later Novartis Pharma AG, he became head of the Biophysics Group, head of the In-vivo Models Unit and finally head of the Analytical and Imaging Science Unit within Discovery Technologies at the Novartis Institutes for Biomedical Research. In this function he was also deputy head of Discovery Technologies until 2005. In 1997 he became Privat Dozent for Biophysics at the University of Basel. Since March 2005, he is member of the Research Council of the Swiss National Science Foundation.
Markus Rudin is heading a research group at the animal imaging center of UZH and ETH located at ETH Hönggerberg focusing on MRI and optical imaging methods (fluorescence tomography). His research focus is the development of non-invasive imaging techniques for studying structure, physiology, and metabolism of tissue as well as cellular and molecular events in the intact organism, in particular assays for monitoring signal transduction pathways. Biomedical applications are in neuroscience and metabolic diseases.
Practical information
- Informed public
- Free
Organizer
Contact
- Institute of Bioengineering (IBI, Christina Mattsson)